Reckitt Benckiser unveils sustainability report
PARSIPPANY, N.J. — Reckitt Benckiser has achieved 75% of its target goal for the company’s Carbon 20 program, RB said in its sustainability report.
The Carbon 20 program, which was launched in 2007, is an initiative set by RB to reduce its own carbon footprint by 20% by 2020.
Additionally, RB also said in the report that all of its household products now tout 100% non-PVC packaging. This includes such brands as Finish, Vanish, Lysol, Harpic and Air Wick.
"Focusing on sustainability is right for our business, right for our industry, and right for society," Reckitt Benckiser CEO Rakesh Kapoor said. "We set ambitious targets for ourselves, and I am pleased that we are on-track to exceed them. RB’s strategy has always been to grow our business thus benefitting consumers, customers, employees, suppliers, communities and shareholders while simultaneously reducing negative impacts, especially on the environment. I am proud of our performance to date, and I know we will continue to improve."
To access the complete report, click here.
Kroger installs Avery Weigh-Tronix Eyecon pharmacy automation machines
LIVONIA, Mich. — Kroger is installing Avery Weigh-Tronix’s tabletop pharmacy automation systems in its stores, Avery said.
The Eyecon is an automated prescription validation, counting and filling system that Avery said enhances inventory management by improving filling accuracy. The machine includes the Visual Counting System, using machine vision technology that increases counting and filling speed by up to 76% over manual counting and filling with a camera mounted above the counting tray that captures five images per second and counts pills within 200 milliseconds.
"Using the Eyecon to count solid-dosage form products saves us time," Kroger pharmacy project manager Mike Menkhaus said. "We noticed a difference, particularly for product audits and physical inventory counts, making the system a great investment."
Breast cancer drug may increase diabetes risk among older women
NEW YORK — A popular breast cancer treatment may pose an increased risk of diabetes among older women, according to a new study.
The research, which was published in the latest issue of Cancer, found that among more than 14,000 breast cancer survivors, ages 65 years and up, 10% were diagnosed with diabetes over a 5-year period. However, the likelihood of developing diabetes was 25% more among those taking breast cancer drug tamoxifen.
Despite the increased risk, the researchers did note that additional factors (i.e., obesity and family history) could influence the increased risk and that the results do not prove that tamoxifen directly causes the development of diabetes. Further investigation is needed to explore the association, the study authors concluded.